

BARI 2D Publications

1. Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: Rationale for the BARI 2D trial. *Circulation*. 2003; 107(4):636-642.
2. Iskandrian AE, Heo J, Mehta D, Tauxe EL, Yester M, Hall MB, MacGregor JM. Gated SPECT perfusion imaging for the simultaneous assessment of myocardial perfusion and ventricular function in BARI 2D: An initial report from the Nuclear Core Laboratory. *Journal of Nuclear Cardiology*. 2006; 13:83-90.
3. Detre KM, Frye RL, Genuth S, guest editors. A symposium: treatment of coronary artery disease and type 2 diabetes: the rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *American Journal of Cardiology* 2006; 97(suppl 12A):1G-65G.
4. Steiner G for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Statement of the problem. *American Journal of Cardiology* 2006; 97(suppl 12A):3G-8G.
5. Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Hypotheses, design and methods for the Bypass Angioplasty Revascularization Investigation 2 (BARI 2D) trial. *American Journal of Cardiology* 2006; 97(suppl 12A):9G-19G.
6. Magee MF, Isley WL for the BARI 2D Trial Investigators. Rationale, Design, and Methods for Glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *American Journal of Cardiology* 2006; 97(suppl 12A):20G-30G.
7. Barsness GW, Gersh BJ, Brooks MM, and Frye RL for the BARI 2D Trial Investigators. Rationale for the Revascularization Arm for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *American Journal of Cardiology* 2006; 97(suppl 12A):31G-40G.
8. Albu J, Gottlieb SH, August P, Nesto RW, and Orchard TJ for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Modifications of coronary risk factors. *American Journal of Cardiology* 2006; 97(suppl 12A):41G-52G. PMC2670550
9. Sobel BE for the BARI 2D Trial Investigators. Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial: Synergies and Opportunities. *American Journal of Cardiology* 2006; 97(suppl 12A):53G-58G.
10. Hlatky MA, Melsop KA, and Boothroyd DB for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease. *American Journal of Cardiology* 2006; 97(suppl 12A):59G-65G.
11. Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *American Heart Journal* 2008 Sep;156(3):528-536, 536.e1-5. PMC2701266

12. Pambianco G, Lombardero M, Bittner V, Forker A, Kennedy F, Krishnaswami A, Mooradian AD, Pop-Busui R, Rana JS, Rodriguez A, Steffes M, Orchard TJ. Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Preventive Cardiology* 2009; 12:9-18. PMC2717619
13. Schwartz L, Kip KE, Alderman E, Lu J, Bates ER, Srinivas V, Bach RG, Mighton LD, Feit F, King SB III, Frye RL for the BARI 2D Study Group. Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). *American Journal of Cardiology* 2009; 103(5):632-638.
14. Pop-Busui R, Lu J, Lopes N, Jones TLZ for the BARI 2D Study Group. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. *Journal of the Peripheral Nervous System* 2009; 14:1-13. PMC2692660
15. Schneider DJ, Hardison RM, Lopes N, Sobel BE, Brooks MM and the Pro-Thrombosis Ancillary Study Group. Association between increased platelet p-selectin expression and obesity in patients with type 2 diabetes: A BARI 2D substudy. *Diabetes Care* 2009; 32:944-949. PMC2671133
16. Kim LJ, King SB III, Kent K, Brooks MM, Kip KE, Abbott JD, Jacobs AK, Rihal C, Hueb WA, Alderman E, Pena Sing IR, Attubato MJ, Feit F for the BARI 2D Study Group. Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D trial. *Journal of the American College of Cardiology: Cardiovascular Interventions* 2009; 2:384-392.
17. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *New England Journal of Medicine* 2009; 11; 360(24):2503-15. PMC2863990
18. Pop-Busui R, Lombardero M, Lavis V, Forker A, Green J, Korytkowski M, Sobel BE, Jones TLZ, and the BARI 2D Study Group. Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). *American Journal of Cardiology* 2009; 104(1):52-58. PMC2756995
19. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL, and the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. *Circulation* 2009; 120: 2529 - 2540. PMC2830563
20. Hlatky MA, Boothroyd DB, Melsop KA, Kennedy L, Rihal C, Rogers WJ, Venkitachalam L, Brooks MM, for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. *Circulation* 2009;120:2550-2558. PMC3403834

21. McBane RD, Hardison RM, Sobel BE, BARI 2D Study Group. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and d-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial). *American Journal of Cardiology* 2010; 105(1): 17-24. PMC2814593
22. Escobedo J, Rana JS, Lombardero MS, Albert SG, Davis, AM, Kennedy FP, Mooradian AD, Robertson DG, Srinivas VS, Gebhart SSP, and for the BARI 2D Study Group. Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary artery disease in the BARI 2D Study. *Mayo Clinic Proceedings* 2010 85(1):41-46. PMC2800289
23. Albu JB, Lu J, Mooradian AD, Krone RJ, Nesto RW, Porter MH, Rana JS, Rogers WJ, Sobel BE, Gottlieb SH and for the BARI 2D Study Group. Relationships of obesity and fat distribution with atherothrombotic risk factors: Baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Obesity (Silver Spring)*. 2010 May;18(5):1046-54.
24. Hlatky MA, Chung S-C, Escobedo J, Hillegass WB, Melsop K, Rogers W, Brooks MM for the BARI 2D Study Group. The effect of obesity on quality of life in patients with diabetes and coronary artery disease. *Am Heart J*: 2010;159:292-300.
25. Thomas SB, Sansing VV, Davis A, Magee M, Massaro E, Srinivas VS, Helmy T, Desvigne-Nickens P, Brooks MMB, and BARI 2D Study Group. Racial Differences in the Association Between Self-Rated Health Status and Objective Clinical Measures Among Participants in the BARI 2D Trial. *Am J Public Health* 2010;100 Suppl 1:S269-76. PMC2837445
26. Rana JS, Hardison RM, Pop-Busui R, Brooks MM, Jones TLZ, Nesto RW, Bourassa MG, and the BARI 2D Investigators. Resting heart rate and metabolic syndrome in patients with diabetes and coronary artery disease in Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Preventive Cardiology* 2010;13:112-6.
27. Wall BM, Hardison RM, Molitch ME, Marroquin OC, McGill JB, August PA; for the BARI 2D Study Group. High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: The BARI 2D baseline data. *Am J Med Sci*. 2010 Mar 31;339:401-10.
28. Grogan M, Jenkins M, Sansing VV, MacGregor J, Brooks MM, Julien-Williams P, Amendola A, Abbott JD. Health insurance status and control of diabetes and coronary artery disease risk factors on enrollment into the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Diabetes Educ*.36(5):774-83.
29. Brooks MM, Chung SC, Helmy T, Hillegass WB, Escobedo J, Melsop KA, Massaro EM, McBane RD, Hyde P, Hlatky MA; the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. *Circulation*. 2010;122:1690-99. PMC2964421

- 30 Tamis-Holland JE, Lu J, Bittner V, Magee MF, Lopes N, Adler D, Kip KE, Schwartz L, Groenewoud Y, Jacobs AK, for the BARI 2D Study Group. Sex, clinical symptoms, and angiographic findings in patients with diabetes mellitus and coronary artery disease (from the Bypass Angioplasty Revascularization Investigation [BARI] 2D). *American Journal of Cardiology*. 2011;107(7):980-985.
- 31 Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venjitachalam L, Tsapatsaris NP, Piemonte TC, Lago RM, Rutter MK, Nesto RW, and the BARI 2D Investigators. The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Diabetes Care*. 2011; 34 (2):464-467. PMC3024368
- 32 Beohar N, Davidson CJ, Massaro E, Srinivas VS, Sansing VV, Zonszein J, Davis AM, Helmy T, Lopes N, Thomas SB, Brooks MM, and the BARI 2D Study Group. The Impact of race/ethnicity on baseline characteristics and the burden of coronary atherosclerosis in the Bypass Angioplasty Revascularization Investigation of Type 2 Diabetes (BARI 2D). *American Heart Journal*. 2011;161:755-63.
- 33 Dagenais GR, Lu J, Faxon DP, Kent K, Lago RM, Lezama C, Hueb W, Weiss W, Slater J, Frye RL, for the BARI 2D Trial Research Group. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. *Circulation*. 2011;123:1492-500.
- 34 Chung S-C, Hlatky MA, Stone RA, Rana, JS, Escobedo J, Rogers WJ, Bromberger JT, Kelsey SF, Brooks MM, and the BARI 2D Study Group. Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). *American Heart Journal*. 2011;162:184-192. PMC3141323
- 35 Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD, Schneider, DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, Frye RL, and for the BARI 2D Investigators. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes. *Circulation*. 2011;124:695-703.
- 36 Chung S-C, Hlatky MA, Faxon DP, Ramanathan K, Adler D, Mooradian AD,, Rihal C, Stone RA, Bromberger JT, Kelsey SF, Brooks MM and the BARI 2D Study Group. The effect of age on clinical outcomes and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D). *J Am Coll Cardiol*. 2011;58(8):810-9. PMC3164969
- 37 Cresci S, Wu J, Province MA, Spertus JA, Steffes M, McGill JB, Alderman EL, Brooks MM, Kelsey SF, Frye RL, Bach RG. Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial/clinical perspective. *Circulation*; 2011;124(13):1426-34.
- 38 Krishnaswami AR, Hardison R, Nesto RW, Sobel, B. "Presentation in patients with angiographically documented coronary artery disease and type ii diabetes mellitus (from the BARI 2D clinical trial)." *The American Journal of Cardiology* 2012;109(1): 36-41.

- 39 Schwartz L, Bertolet M, Feit F, Fuentes F, Sako EY, Toosi MS, Davidson CJ, Ikeno F, King SB. Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). *Circulation: Cardiovascular Interventions*. 2012;5:166-173.
- 40 Shaw LJ, Cerqueira MD, Brooks MM, Althouse AD, Sansing VV, Beller GA, Pop-Busui R, Taillefer R, Chaitman BR, Gibbons RJ, Heo J, Iskandrian AE. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *J Nucl Cardiol*. 2012;19(4):658-69.
- 41 Brooks MM, Chaitman BR, Nesto RW, Hardison RM, Feit F, Gersh BJ, et al. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the BARI 2D trial. *Circulation*. 2012;126:2115-24.
- 42 Abbott JD, Lombardero MS, Barsness GW, Pena-Sing I, Buitrón LV, Singh P, et al. Ankle-brachial index and cardiovascular outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. *American Heart Journal*. 2012;164:585-90.
- 43 Bertolet M, Brooks MM, Bittner V. Tree-based identification of subgroups for time-varying covariate survival data. *Stat Methods Med Res*. 2012 Oct 14. [epub ahead of print]